Becton Dickinson Reports Strong Q4 2024 Financial Results

Details

The company reported a 6.9% increase in reported revenues, with a 7.4% growth on a foreign currency-neutral basis. Diluted earnings per share (EPS) from continuing operations surged by 173.6% to $1.45, and adjusted diluted EPS grew by 11.4% to $3.81. The company also provided fiscal 2025 revenue guidance of 8.9% to 9.4% growth, with organic revenue growth guidance of 4.0% to 4.5%. The financial performance was driven by strong demand across all business segments, particularly in Medication Delivery Solutions and Medication Management Solutions within the BD Medical segment.

Items reported

Exhibits (1)

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.